A SARS-CoV-2 RBD vaccine fused to the chemokine MIP-3α elicits sustained murine antibody responses over 12 months and enhanced lung T-cell responses
Article in Frontiers in Immunology (February 2024)
The most recent citing publications are shown below. View all 43 publications that cite this research output on Dimensions.
Article in Frontiers in Immunology (February 2024)
Article in Immunotherapy Advances (January 2023)
Article in Vaccine (March 2022)